Rolf C R Ljung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9096032/publications.pdf

Version: 2024-02-01

66 papers	2,997 citations	201385 27 h-index	161609 54 g-index

71 all docs	71 docs citations	71 times ranked	1814 citing authors

#	Article	IF	Citations
1	Silent variant in F8 :c.222G>T (p.Thr74Thr) causes a partial exon skipping in a patient with mild hemophilia A. Molecular Genetics & Genomic Medicine, 2022, 10, e1856.	0.6	1
2	Droplet digital PCR and mileâ€post analysis for the detection of F8 int1h inversions. Journal of Thrombosis and Haemostasis, 2021, 19, 732-737.	1.9	2
3	Practical considerations for nonfactorâ€replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia, 2021, 27, 340-350.	1.0	15
4	Principles of care for acquired hemophilia. European Journal of Haematology, 2021, 106, 762-773.	1.1	11
5	Identification of F8 rearrangements in carrier and nonâ€carrier mothers of haemophilia A patients. Haemophilia, 2021, 27, e654-e658.	1.0	0
6	Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1121-1130.	1.0	2
7	Registries and databasesâ€”A European perspective. Haemophilia, 2020, 26, 26-28.	1.0	3
8	Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica, 2020, 106, 123-129.	1.7	60
9	Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thrombosis Research, 2020, 189, 96-101.	0.8	2
10	Genetic screening of children with suspected inherited bleeding disorders. Haemophilia, 2020, 26, 314-324.	1.0	6
11	Detection of F8 int22h inversions using digital droplet PCR and mileâ€post assays. Journal of Thrombosis and Haemostasis, 2020, 18, 1039-1049.	1.9	4
12	Pulmonary Embolism in Children with Asymptomatic Proximal Deep Vein Thromboembolism: Single-Center Experience from Sweden. Blood, 2020, 136, 4-4.	0.6	0
13	Predicting Thrombosis Recurrence in Children: The Role of Thrombophilia Testing. Blood, 2020, 136, 2-3.	0.6	0
14	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	0.6	71
15	Targeted re-sequencing of F8, F9 and VWF: Characterization of Ion Torrent data and clinical implications for mutation screening. PLoS ONE, 2019, 14, e0216179.	1.1	5
16	Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica, 2019, 104, 2100-2106.	1.7	30
17	Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediateâ€and highâ€dose prophylaxis. Haemophilia, 2019, 25, 244-251.	1.0	16
18	Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficultâ€toâ€treat patients. European Journal of Haematology, 2019, 102, 111-122.	1.1	78

#	Article	IF	Citations
19	How I manage patients with inherited haemophilia A and B and factor inhibitors. British Journal of Haematology, 2018, 180, 501-510.	1.2	36
20	Haemophilia B: Where are we now and what does the future hold?. Blood Reviews, 2018, 32, 52-60.	2.8	41
21	Practical aspects of extended half-life products for the treatment of haemophilia. Therapeutic Advances in Hematology, 2018, 9, 295-308.	1.1	85
22	Prevention and Management of Bleeding Episodes in Children with Hemophilia. Paediatric Drugs, 2018, 20, 455-464.	1.3	13
23	Primary prophylaxis in haemophilia care: Guideline update 2016. Blood Cells, Molecules, and Diseases, 2017, 67, 81-85.	0.6	29
24	Outcome measures for adult and pediatric hemophilia patients with inhibitors. European Journal of Haematology, 2017, 99, 103-111.	1.1	8
25	The care of a child with a newly diagnosed immune thrombocytopenia. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 1554-1555.	0.7	1
26	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307.	1.2	56
27	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 2017, 117, 2274-2282.	1.8	13
28	Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfusion, 2017, 15, 77-84.	0.3	6
29	Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thrombosis and Haemostasis, 2016, 115, 913-920.	1.8	27
30	Pain and pain management in haemophilia. Blood Coagulation and Fibrinolysis, 2016, 27, 845-854.	0.5	66
31	Aspects of prophylactic treatment of hemophilia. Thrombosis Journal, 2016, 14, 30.	0.9	28
32	Can a â€œcenter effectâ€•explain the higher frequency of inhibitors for a second-generation recombinant factor VIII product?. Blood, 2015, 126, 2164-2165.	0.6	1
33	Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica, 2015, 100, e84-e86.	1.7	27
34	The current status of prophylactic replacement therapy in children and adults with haemophilia. British Journal of Haematology, 2015, 169, 777-786.	1.2	52
35	Various regimens for prophylactic treatment of patients with haemophilia. European Journal of Haematology, 2015, 94, 11-16.	1.1	7
36	Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatric Blood and Cancer, 2014, 61, 706-711.	0.8	41

#	Article	IF	Citations
37	Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?. Thrombosis Research, 2014, 133, 967-971.	0.8	10
38	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 231-239.	13.9	383
39	Hemophilia and prophylaxis. Pediatric Blood and Cancer, 2013, 60, S23-6.	0.8	21
40	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood, 2013, 122, 1129-1136.	0.6	200
41	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	0.6	287
42	Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood, 2013, 121, 3946-3952.	0.6	59
43	Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. European Journal of Haematology, 2012, 88, 371-379.	1.1	50
44	How to manage invasive procedures in children with haemophilia. British Journal of Haematology, 2012, 157, 519-528.	1.2	17
45	The Fourth Annual Meeting of the International Network for Pediatric Hemophilia: Current Challenges and Recommendations in the Clinical Care of Children with Hemophilia. Transfusion Medicine and Hemotherapy, 2010, 37, 209-212.	0.7	2
46	Prophylactic therapy in haemophilia. Blood Reviews, 2009, 23, 267-274.	2.8	49
47	Intracranial haemorrhage in haemophilia A and B. British Journal of Haematology, 2008, 140, 378-384.	1.2	162
48	The risk associated with indwelling catheters in children with haemophilia. British Journal of Haematology, 2007, 138, 580-586.	1.2	48
49	Studies of chronic ITP in children and adolescents. Pediatric Blood and Cancer, 2006, 47, 660-661.	0.8	0
50	Central venous catheters in children with haemophilia. Blood Reviews, 2004, 18, 93-100.	2.8	24
51	Genetic Counseling of Hemophilia Carriers. Seminars in Thrombosis and Hemostasis, 2003, 29, 031-036.	1.5	17
52	Somatic Mosaicism in Hemophilia A: A Fairly Common Event. American Journal of Human Genetics, 2001, 69, 75-87.	2.6	144
53	Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. British Journal of Haematology, 2001, 113, 81-86.	1.2	68
54	Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. British Journal of Haematology, 1999, 105, 1109-1113.	1.2	258

#	Article	IF	Citations
55	Origin of mutation in sporadic cases of haemophilia A. British Journal of Haematology, 1999, 106, 870-874.	1.2	40
56	Can haemophilic arthropathy be prevented?. British Journal of Haematology, 1998, 101, 215-219.	1.2	49
57	Factor IX Inhibitors and Anaphylaxis in Hemophilia B. The American Journal of Pediatric Hematology/oncology, 1997, 19, 23-27.	1.3	168
58	Inversions of the factor VIII gene in Swedish patients with severe haemophilia A. European Journal of Haematology, 1995, 54, 310-313.	1.1	10
59	Genetic Diagnosis of Hemophilia A. Pediatric Hematology and Oncology, 1994, 11, 9-11.	0.3	1
60	Haemoglobin KÃ¶ln as de novo mutations in Sweden: Diagnosis by PCR and specific enzymatic cleavage. European Journal of Haematology, 1994, 52, 156-161.	1.1	3
61	Origin of mutation in sporadic cases of haemophiliaâ€B. European Journal of Haematology, 1992, 48, 142-145.	1.1	19
62	Haplotype Analysis of Identical Factor IX Mutants Using PCR. Thrombosis and Haemostasis, 1992, 67, 066-069.	1.8	16
63	Moderate haemophilia B in a female carrier caused by preferential inactivation of the paternal X chromosome. European Journal of Haematology, 1991, 47, 257-261.	1.1	18
64	IMMUNORADIOMETRIC ASSAY OF INHIBITORS OF ANTIHAEMOPHILIC FACTOR A. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 1019-1023.	0.7	3
65	Genetic Variants of Haemophilia B Detected by Immunoradiometric Assay: Implications for Prenatal Diagnosis. Pediatric Research, 1982, 16, 256-258.	1.1	10
66	Inheritable Molecular Variants of Moderate and Mild Hemophilia A. Acta Medica Scandinavica, 1981, 209, 11-16.	0.0	6